Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Emory University School of Medicine
Atlanta, Estados UnidosPublicaciones en colaboración con investigadores/as de Emory University School of Medicine (34)
2024
-
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study
The Lancet Oncology, Vol. 25, Núm. 5, pp. 668-682
-
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
2023
-
An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS)
Annals of Surgery, Vol. 277, Núm. 5, pp. 821-828
-
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Blood cancer discovery, Vol. 4, Núm. 5, pp. 365-373
2022
-
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293
-
Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis
JACC: Cardiovascular Imaging, Vol. 15, Núm. 11, pp. 1883-1896
2021
-
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
The Lancet Oncology, Vol. 22, Núm. 1, pp. 142-154
-
Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C
Journal of Clinical Endocrinology and Metabolism, Vol. 106, Núm. 2, pp. E660-E674
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Idecabtagene vicleucel in relapsed and refractory multiple myeloma
New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716
-
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, Núm. 5, pp. 1570-1584
-
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Blood Cancer Journal, Vol. 11, Núm. 6
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212
-
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
The Lancet, Vol. 398, Núm. 10315, pp. 1984-1996
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
-
Worldwide barriers to genetic testing for movement disorders
European Journal of Neurology, Vol. 28, Núm. 6, pp. 1901-1909
2019
-
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469
2017
-
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
British Journal of Haematology, Vol. 178, Núm. 6, pp. 896-905
-
Intertumoral Heterogeneity within Medulloblastoma Subgroups
Cancer Cell, Vol. 31, Núm. 6, pp. 737-754.e6